Eikon Therapeutics, Inc. (NASDAQ:EIKN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have been assigned a consensus rating of “Hold” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $25.20.

Several analysts recently weighed in on EIKN shares. Wedbush reduced their price objective on Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings began coverage on Eikon Therapeutics in a research note on Monday, June 1st. They set a “sell (e-)” rating for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Eikon Therapeutics in a research note on Tuesday, June 2nd. Finally, Wall Street Zen lowered shares of Eikon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 5th.

Eikon Therapeutics Price Performance

Shares of NASDAQ:EIKN opened at $11.22 on Friday. Eikon Therapeutics has a 1 year low of $7.90 and a 1 year high of $17.40. The company has a market capitalization of $607.44 million and a PE ratio of -4.56. The company has a 50 day moving average price of $10.47.

Eikon Therapeutics (NASDAQ:EIKN) last issued its quarterly earnings results on Monday, March 30th. The company reported ($26.23) earnings per share (EPS) for the quarter.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.